AMCY Stock Overview
ACS Global, Inc. engages in the collection, processing, and long-term storage of stem cells.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ACS Global, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.00 |
| 52 Week High | US$5.00 |
| 52 Week Low | US$2.37 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 57.89% |
| 5 Year Change | 400.00% |
| Change since IPO | -98.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| AMCY | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | -1.3% | -3.5% |
| 1Y | n/a | -2.9% | 20.2% |
Return vs Industry: Insufficient data to determine how AMCY performed against the US Healthcare industry.
Return vs Market: Insufficient data to determine how AMCY performed against the US Market.
Price Volatility
| AMCY volatility | |
|---|---|
| AMCY Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AMCY has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AMCY's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.americancryostem.com |
ACS Global, Inc. engages in the collection, processing, and long-term storage of stem cells. The company’s services would allow individuals to privately preserve their stem cells for potential future use in cell therapy. The company was formerly known as American CryoStem Corp. and changed its name to ACS Global, Inc. in June 2011.
ACS Global, Inc. Fundamentals Summary
| AMCY fundamental statistics | |
|---|---|
| Market cap | US$171.48m |
| Earnings (TTM) | US$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs AMCY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMCY income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$0 |
| Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did AMCY perform over the long term?
See historical performance and comparison